"Sodium Oxybate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The sodium salt of 4-hydroxybutyric acid. It is used for both induction and maintenance of ANESTHESIA.
- Sodium Oxybate
- Oxybate, Sodium
- Sodium Oxybutyrate
- Oxybutyrate, Sodium
- Sodium gamma-Hydroxybutyrate
- Sodium gamma Hydroxybutyrate
- 4-Hydroxybutyrate Sodium
- 4 Hydroxybutyrate Sodium
- Oxybate Sodium
Below are MeSH descriptors whose meaning is more general than "Sodium Oxybate".
Below are MeSH descriptors whose meaning is more specific than "Sodium Oxybate".
This graph shows the total number of publications written about "Sodium Oxybate" by people in this website by year, and whether "Sodium Oxybate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Sodium Oxybate" by people in Profiles.
Dauvilliers Y, Šonka K, Bogan RK, Partinen M, Del Rio Villegas R, Foldvary-Schaefer N, Skowronski R, Chen A, Black J, Skobieranda F, Thorpy MJ. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications. CNS Drugs. 2022 06; 36(6):633-647.
Roth T, Dauvilliers Y, Thorpy MJ, Kushida C, Corser BC, Bogan R, Rosenberg R, Dubow J, Seiden D. Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. CNS Drugs. 2022 04; 36(4):377-387.
Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, Morse AM, Šonka K, Thorpy MJ, Mignot E, Chandler P, Parvataneni R, Black J, Sterkel A, Chen D, Skobieranda F, Bogan RK. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022 01; 21(1):53-65.
Bogan RK, Thorpy MJ, Dauvilliers Y, Partinen M, Del Rio Villegas R, Foldvary-Schaefer N, Skowronski R, Tang L, Skobieranda F, Šonka K. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021 03 12; 44(3).
Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020 04; 68:97-109.
Black J, Swick T, Bogan R, Lai C, Carter LP. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016 08; 24:57-62.
Bogan RK, Roth T, Schwartz J, Miloslavsky M. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. J Clin Sleep Med. 2015 Apr 15; 11(4):427-32.
Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009 Jun; 10(6):661-3.
Barth KS, Hines S, Albanese RP. Permanent neurologic damage from chronic gamma hydroxybutyrate abuse. Am J Addict. 2006 Nov-Dec; 15(6):483-4.
Myrick H, Brady KT, Malcolm R. New developments in the pharmacotherapy of alcohol dependence. Am J Addict. 2001; 10(s1):s3-s15.